ARMONAIR DIGIHALER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARMONAIR DIGIHALER (ARMONAIR DIGIHALER).
ARMONAIR DIGIHALER contains fluticasone furoate and umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, modulating gene expression to reduce inflammatory mediators. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors, causing bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, leading to smooth muscle relaxation and bronchodilation.
| Metabolism | Fluticasone furoate is primarily metabolized by CYP3A4. Umeclidinium is primarily metabolized by CYP2D6 and CYP3A4, with subsequent excretion via biliary and renal pathways. Vilanterol is primarily metabolized by CYP3A4. |
| Excretion | Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30% |
| Half-life | Terminal elimination half-life of unchanged arformoterol is approximately 26 hours (range 21-30 hours). This supports twice-daily dosing with approximately 2 days to steady state. |
| Protein binding | Approximately 52-65% bound to human plasma proteins (mainly albumin). |
| Volume of Distribution | Approximately 2.5 L/kg (mean Vd at steady state = 204 L for a 70 kg individual), indicating extensive tissue distribution. |
| Bioavailability | Inhalation: approximately 5-7% of the delivered dose reaches systemic circulation (low systemic bioavailability due to pulmonary deposition and first-pass metabolism of swallowed portion). |
| Onset of Action | Inhalation: within 7 minutes (based on FEV1 improvement); peak effect at 1-3 hours. |
| Duration of Action | Approximately 12 hours (bronchodilation maintained over the dosing interval with twice-daily administration). Clinical trials show sustained FEV1 improvement at 12 hours post-dose. |
2 inhalations (55 mcg each) orally twice daily for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Not indicated for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use with caution due to potential for greater sensitivity and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARMONAIR DIGIHALER (ARMONAIR DIGIHALER).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Umeclidinium is excreted in rat milk; vilanterol is likely excreted in human milk based on molecular weight. M/P ratio not available. Caution advised; consider benefits of breastfeeding and importance of drug to mother. |
| Teratogenic Risk | ARMONAIR DIGIHALER contains umeclidinium and vilanterol. In animal studies, umeclidinium showed no evidence of teratogenicity at exposures up to 50 times the maximum recommended human dose (MRHD). Vilanterol showed increased fetal loss and skeletal variations at exposures 9 times MRHD. Human data are insufficient; use only if benefit outweighs risk. In first trimester, risk cannot be excluded; in second and third trimesters, use may be associated with decreased placental perfusion and fetal growth restriction due to beta-2 agonist effects. |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists (LABAs), such as vilanterol, increase the risk of asthma-related death. Therefore, the use of ARMONAIR DIGIHALER for the treatment of asthma without a concomitant long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. This warning does not apply to COPD.
| Serious Effects |
["Primary treatment of status asthmaticus or acute episodes of asthma or COPD requiring intensive measures","Hypersensitivity to any component of the product","Use with other LABA-containing products","Severe hypersensitivity to milk proteins (lactose monohydrate contains milk proteins)"]
| Precautions | ["Risk of asthma-related death (see black box warning)","Deterioration of disease and acute episodes: not indicated for acute bronchospasm","Cardiovascular effects: increased heart rate, hypertension, arrhythmias","Paradoxical bronchospasm","Hypersensitivity reactions including anaphylaxis","Increased risk of pneumonia in COPD patients","Hypercorticism and adrenal suppression (with higher doses of fluticasone furoate)","Reduction in bone mineral density with long-term use","Immunosuppression and increased risk of infections","Cataracts and glaucoma"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal pulmonary function, heart rate, blood pressure, and signs of beta-agonist toxicity (tremor, palpitations). Assess fetal growth via ultrasound if used long-term in second and third trimesters due to potential for fetal growth restriction. Monitor for preterm labor symptoms. |
| Fertility Effects | No human studies on fertility. Animal studies: umeclidinium had no effect on fertility in rats; vilanterol decreased fertility indices in rats at exposures 4 times MRHD. Effect on human fertility unknown. |
| Food/Dietary |
| No specific food interactions. Avoid excessive caffeine or stimulants as they may increase cardiovascular side effects. |
| Clinical Pearls | ARMONAIR DIGIHALER (arformoterol tartrate) is a long-acting beta2-agonist (LABA) for maintenance treatment of COPD. Do not use for acute exacerbations. Monitor for paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension), and hypokalemia. Do not exceed the recommended dose (one inhalation twice daily). Not indicated for asthma. |
| Patient Advice | Use only as a maintenance treatment for COPD, not for sudden breathing problems. · Take one inhalation twice daily (morning and evening) every day, even if symptom-free. · Rinse mouth with water after each use to prevent oral thrush. · Do not use more than prescribed; overdose can cause chest pain, fast heartbeat, or seizures. · Seek immediate medical help if breathing worsens or you experience chest pain, irregular heartbeat, or swelling of face/lips. · Store inhaler at room temperature, away from heat and moisture; discard after 28 days of first use. · Know your rescue inhaler (e.g., albuterol) and use it only for acute symptoms. |